Prospective observational study investigating Chemotherapies in untreated patients with newly diagnosed primary CNS-Lymphoma (PCNSL)

Prospective observational study investigating Chemotherapies in untreated patients with newly diagnosed primary CNS-Lymphoma (PCNSL) - NOA13

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011220

Enrollment

200

Registered

2020-04-14

Start date

2016-12-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary CNS-Lymphoma

Interventions

Group 1: The aim is to enrol patients in fitst-line therapy with PCNSL over the age of 18 years and without contraindications for intensive chemotherapy (cf. inclusion/exclusion criteria). We would l

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PZNSL confirmed in histology, cytology or immunocytology No Lymphoma manifestations outside the CNS No contraindications for intensive chemo therapy Consent to paticipation

Exclusion criteria

Exclusion criteria: Lymphoma manifestations outside the CNS, preceding or planned WBRT, previous PCNSL therapy other than corticosteroids, active uncontrolled infection, immunosuppression, concomitant immunsuppressive therapy status post organ Transplantation, HIV infection, concomitant malignancy in the last 5 years other than basal cell carcinoma or carcinoma in situ of the Cervix,

Design outcomes

Primary

Measure	Time frame
Not applicable. The goal ist to evaluate the different protocols of chemotherapy in effectiveness (over all survival, progression free survival)and tolerance (toxicity, therapy discontinuations)	—

Countries

Germany

Contacts

Public ContactSylvia Rekowski

Knappschaftskrankenhaus Bochum-Langendreer

Sylvia.rekowski@kk-bochum.de0234-29983703

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026